Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.

[1]  James D Sullivan,et al.  Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence. , 2015, Surgical oncology.

[2]  H. Putter,et al.  Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. , 2014, Journal of the National Cancer Institute.

[3]  J. Hornberger,et al.  Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer , 2014, PharmacoEconomics.

[4]  S. Dakhil,et al.  Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. , 2014, The oncologist.

[5]  M. Broder,et al.  Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer , 2014, Current medical research and opinion.

[6]  Yen-Lin Lee,et al.  Differences in Survival between Colon and Rectal Cancer from SEER Data , 2013, PloS one.

[7]  M. Coleman,et al.  Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study , 2013, BMJ Open.

[8]  A. Glas,et al.  Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer , 2013, Annals of surgery.

[9]  R. Salazar,et al.  Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients. , 2013 .

[10]  R. Schilsky,et al.  Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Paik,et al.  Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). , 2012 .

[12]  D. Kerr,et al.  Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Sridhar Ramaswamy,et al.  Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Begun,et al.  Association between lymph node evaluation for colon cancer and node positivity over the past 20 years. , 2011, JAMA.

[16]  Maureen A. Smith,et al.  Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Dotan,et al.  Challenges in the management of stage II colon cancer. , 2011, Seminars in oncology.

[18]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[19]  S. Paik,et al.  Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Sargent,et al.  Revised TN categorization for colon cancer based on national survival outcomes data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Soonmyung Paik,et al.  Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.

[23]  R. Labianca,et al.  Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Labianca,et al.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Washington,et al.  Lymphovascular Invasion in Colorectal Cancer: An Interobserver Variability Study , 2008, The American journal of surgical pathology.

[26]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[27]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[29]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[30]  L. V. van't Veer,et al.  Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Teutsch,et al.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.